Bayer to provide Magnevist, Ultravist for Amerinet

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

Bayer HealthCare Pharmaceuticals has been awarded a two-year contrast media contract by Amerinet, to make Magnevist (gadopentetate dimeglumine) injection and Ultravist (iopromide) injection available to members of the Amerinet network.

The agreement is effective March 1 through 2010. 

According to St. Louis-based Amerinet, it covers Magnevist in multiple presentations, including 5, 10, 15 and 20 mL single-dose vials, 50 and 100 mL pharmacy bulk packages, and 10, 15 and 20 mL pre-filled syringes of Magnevist. 

Ultravist will be available in four concentrations (150, 240, 300 and 370 mgI) and in a variety of product presentations, including 500 mL pharmacy bulk packages for the 300 mgI and 370 mgI concentrations, according to Bayer.